Mannan-mediated gene delivery for cancer immunotherapy

Immunology

Volumn 120, Issue 3, 2007, Pages 325-335

  Tang, Choon K ^a   Lodding, Jodie ^a   Minigo, Gabriela ^a   Pouniotis, Dodie S ^a   Plebanski, Magdalena ^a   Scholzen, Anja ^a   McKenzie, Ian F C ^a   Pietersz, Geoffrey A ^a   Apostolopoulos, Vasso ^a  

^a BURNET INSTITUTE   (Australia)

Author keywords

Cancer; DNA vaccine; Gene therapy; Mannan; Mannose receptor; Oxidized mannan

Indexed keywords

MANNAN; OVALBUMIN; PLASMID DNA; POLYLYSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE TARGETING; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATION KINETICS; PRIORITY JOURNAL; REDUCTION KINETICS; TUMOR;

ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MANNANS; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; OXIDATION-REDUCTION; POLYLYSINE; RECEPTORS, CELL SURFACE; VACCINES, DNA;

EID: 33846923648     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02506.x     Document Type: Article

References (48)

1. Kumar VV, Singh RS, Chaudhuri A. Cationic transfection lipids in gene therapy: successes, set-backs, challenges and promises. Curr Med Chem 2003; 10:1297-306.
2. Schatzlein AG. Targeting of synthetic gene delivery systems. J Biomed Biotechnol 2003; 2:149-58.
3. Cho YW, Kim JD, Park K. Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol 2003; 55:721-34.
4. Cui Z, Mumper RJ. Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carrier Syst 2003; 20:103-37.
5. Ferkol T, Perales JC, Mularo F, Hanson RW. Receptor-mediated gene transfer into macrophages. Proc Natl Acad Sci USA 1996; 93:101-5.
6. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 1994; 91:4086-90.
7. Cotten M, Langle-Rouault F, Kirlappos H, Wagner E, Mechtler K, Zenke M, Beug H, Birnstiel ML. Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. Proc Natl Acad Sci USA 1990; 87:4033-7.
8. Martinez-Fong D, Navarro-Quiroga I. Synthesis of a non-viral vector for gene transfer via the high-affinity neurotensin receptor. Brain Res Brain Res Protoc 2000; 6:13-24.
9. Matulis D, Rouzina I, Bloomfield VA. Thermodynamics of cationic lipid binding to DNA and DNA condensation: roles of electrostatics and hydrophobicity. J Am Chem Soc 2002; 124:7331-42.
10. Zenke M, Steinlein P, Wagner E, Cotten M, Beug H, Birnstiel ML. Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc Natl Acad Sci USA 1990; 87:3655-9.
11. Barratt G, Tenu JP, Yapo A, Petit JF. Preparation and characterization of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta 1986; 862:153-64.
12. Hattori Y, Kawakami S, Suzuki S, Yamashita F, Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem Biophys Res Commun 2004; 317:992-9.
13. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 1995; 92:10128-32.
14. Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF. CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol 1995; 155:5089-94.
15. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996; 14:930-8.
16. Apostolopoulos V, McKenzie IF, Pietersz GA. Breast cancer immunotherapy: current status and future prospects. Immunol Cell Biol 1996; 74:457-64.
17. Acres B, Apostolopoulos V, Balloul JM et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 2000; 48:588-94.
18. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol 2000; 30:1714-23.
19. Bachtiar EW, Sheng KC, Fifis T, Gamvrellis A, Plebanski M, Coloe PJ, Smooker PM. Delivery of a heterologous antigen by a registered Salmonella vaccine (STM1). FEMS Microbiol Lett 2003; 227:211-7.
20. Liu G, Molas M, Grossmann GA, Pasumarthy M, Perales JC, Cooper MJ, Hanson RW. Biological properties of poly-L-lysine-DNA complexes generated by cooperative binding of the polycation. J Biol Chem 2001; 276:34379-87.
21. Apostolopoulos V, Matsoukas J, Plebanski M, Mavromoustakos T. Applications of peptide mimetics in cancer. Curr Med Chem 2002; 9:411-20.
22. Apostolopoulos V, Yuriev E, Ramsland PA et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 2003; 100:15029-34.
23. Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, Layton GT, Hill AV. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997; 15:1280-4.
24. Lee EA, Palmer DR, Flanagan KL et al. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 2002; 70:1417-21.
25. Plebanski M, Flanagan KL, Lee EA et al. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity 1999; 10:651-60.
26. Plebanski M, Gilbert SC, Schneider J et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998; 28:4345-55.
27. Apostolopoulos V, Tang CK, Pietersz GA. Non-viral vector approaches towards gene delivery: current status and future prospects. Current Trends Immunol 2004; 6:21-37.
28. Sato Y, Yamauchi N, Takahashi M et al. In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. Faseb J 2000; 14:2108-18.
29. Khan Z, Hawtrey AO, Ariatti M. New cationized LDL-DNA complexes: their targeted delivery to fibroblasts in culture. Drug Deliv 2003; 10:213-20.
30. Gac S, Coudane J, Boustta M, Domurado M, Vert M. Synthesis, characterization and in vivo behaviour of a norfloxacin-poly (1-lysine citramide imide) conjugate bearing mannosyl residues. J Drug Target 2000; 7:393-406.
31. Derrien D, Midoux P, Petit C, Negre E, Mayer R, Monsigny M, Roche AC. Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. Glycoconj J 1989; 6:241-55.
32. Kunath K, von Harpe A, Fischer D, Kissel T. Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J Control Release 2003; 88:159-72.
33. Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr Mol Med 2001; 1:469-74.
34. Perales JC, Grossmann GA, Molas M, Liu G, Ferkol T, Harpst J, Oda H, Hanson RW. Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asialoglycoprotein receptor. J Biol Chem 1997; 272:7398-407.
35. Diebold SS, Kursa M, Wagner E, Cotten M, Zenke M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J Biol Chem 1999; 274:19087-94.
36. Luo D, Saltzman WM. Nonviral gene delivery: Thinking of silica. Gene Ther 2005; 13:585-6.
37. Mounkes LC, Zhong W, Cipres-Palacin G, Heath TD, Debs RJ. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem 1998; 273:26164-70.
38. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 2005; 7:E61-77.
39. Erbacher P, Bousser MT, Raimond J, Monsigny M, Midoux P, Roche AC. Gene transfer by DNA/glycosylated polylysine complexes into human blood monocyte-derived macrophages. Hum Gene Ther 1996; 7:721-9.
40. Ferkol T, Mularo F, Hilliard J, Lodish S, Perales JC, Ziady A, Konstan M. Transfer of the human Alpha1-antitrypsin gene into pulmonary macrophages in vivo. Am J Respir Cell Mol Biol 1998; 18:591-601.
41. Diebold SS, Lehrmann H, Kursa M, Wagner E, Cotten M, Zenke M. Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum Gene Ther 1999; 10:775-86.
42. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates antitumor CTL responses. Vaccine 2000; 18:3174-84.
43. Sheng K-C, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 2006; 118:372-83.
44. Karanikas V, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100:2783-92.
45. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000; 6:829-37.
46. Karanikas V, Thynne G, Mitchell P et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother 2001; 24:172-83.
47. Loveland BE, Zhao A, White S et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006; 12:869-77.
48. Apostolopoulos V, Pietersz GA, Tsibanis A et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Br Cancer Res 2006; 9:R27.